Merck KGaA to acquire Exelead

By The Science Advisory Board staff writers

January 10, 2022 -- Merck has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately$780 million in cash.

Exelead specializes in complex injectable formulations, including lipid nanoparticle (LNP)-based drug delivery technology that is key in mRNA therapeutics for use in COVID-19 and many other indications. The acquisition of Exelead will accelerate innovation in the process solutions business unit of Merck, according to the firm. The transaction enhances the company's years of experience in producing lipids, a critical component in the formulation of mRNA therapeutics, including COVID-19 vaccines, as well as its mRNA manufacturing capabilities.

Exelead has more than 10 years of experience in all development phases from preclinical development to commercial contract manufacturing for LNP formulations, including fill and finish. Merck intends to continue to invest in mRNA as a modality and will scale this technology at Exelead's existing site in Indianapolis.

The transaction is expected to close in the first quarter of 2022 and is subject to regulatory clearances, as well as the satisfaction of other customary closing conditions.

Merck acquires Chord Therapeutics to expand neuroinflammatory pipeline
Merck has acquired Chord Therapeutics to expand its neurology pipeline and develop Chord's lead drug candidate, CRD1 (cladribine), for the treatment of...
Merck licenses Dragonfly's immunotherapy for tumors
Merck has licensed its second trispecific NK (TrinKet) immunotherapy candidate from Dragonfly Therapeutics for solid tumors.

Copyright © 2022

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter